Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
PaperCitations, authors & open-access status
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 278 citations, 2017 year and hybrid oa status.
278
Citations
2017
Year
hybrid
OA Status